Lung transplantation (LT) has become an accepted therapy for selected patients with advanced lung disease. One of the main limitations to successful LT is rejection of the transplanted organ where chemokines are pivotal mediators. Here, we test the relationship between copy number variation (CNV) in the CCL4L chemokine gene and rejection risk in LT patients (n ¼ 161). Patients with no acute rejection showed a significantly lower mean number of CCL4L copies than patients that showed acute rejection (1.66 vs 1.96, P ¼ 0.014), with an even greater number of gene copies seen in patients with more than one episode of acute rejection (1.66 vs 2.30, P ¼ 0.001). Additionally, patients with X2 CCL4L copies had a significantly higher risk of acute rejection compared with patients that had 0-1 CCL4L copies (odds ratio 2.65; 95% confidence interval, 1.33-5.28; P ¼ 0.0046). A combined analysis of CCL4L CNV and the rs4796195 CCL4L single nucleotide polymorphism demonstrated that the effect of CCL4L copy number in acute rejection is mainly because of the number of copies of the CCL4L1 allelic variant. This finding constitutes the first report of CNV as a correlate factor in allograft rejection.
Introduction
Lung transplantation (LT) is an accepted therapeutic option for a variety of end-stage pulmonary diseases. However, the application of LT is hindered by multiple factors and long-term survival following LT remains low primarily because of immune-mediated complications such as acute rejection and chronic rejection (CR). 1 Acute cellular rejection (AR) is defined by perivascular and bronchiolar inflammation characterized by accumulations of mononuclear cells and eosinophils. 2 But, acute antibody-mediated rejection is not well defined. In CR, bronchiolitis obliterans, which is the most specific pulmonary manifestation, represents the end result of immunological injury to the allograft. 3 Leukocyte migration through vessels and beyond the vascular compartment is dependent, in addition to adhesion molecules, on small chemoattractant proteins called chemokines. 4 Indeed, chemokine-driven accumulation of leukocytes in the graft is a key feature of transplant rejection. 5 Specifically, recent research in animal LT models and human LT recipients has demonstrated the important contribution of chemokines to lung allograft rejection. 6 Previous works have demonstrated that differences in individual genetic background may affect propensity for transplant rejection. 7, 8 In fact, genetic polymorphisms influence the function or expression of key immunoregulatory molecules that either directly or indirectly mediate graft rejection. 9, 10 In past years, common genetic variants of several chemokines have been associated with functional and biological effects, including susceptibility to a great variety of diseases, and there is evidence that chemokine polymorphisms could be one of the factors that define allograft rejection. [11] [12] [13] CCL4L chemokine is a nonallelic copy of CCL4/MIP1b chemokine. CCL4 and CCL4L genes are located at chromosome 17q12 and its mature proteins differ at only a single amino acid. CCL4L gene displays copy number variation (CNV) between individuals.
14 CNV is widespread among normal individuals and is considered an important form of genetic diversity among humans. 15, 16 Variation in copy number can influence transcription or translation of overlapping or nearby genes, and some types of CNV are associated with differential susceptibility to both complex and common diseases. 17, 18 The main aim of the current study was to evaluate the influence of CCL4L gene copy number in LT rejection.
In addition to the CCL4L CNV, we also genotyped two functionally relevant CCL4L single nucleotide polymorphisms (SNPs): rs4796195 and rs3744595. Both SNPs have been previously associated with HIV pathology 19, 20 and, strikingly, the rs4796195 minor allele L2, which encodes different CCL4L transcripts and proteins than the L1 allele, shows among worldwide populations a strong positive correlation with CCL4L copy number. 21 Our results showed a significant association between higher genomic copy number for the CCL4L gene and risk of AR in LT, an association mainly because of the number of CCL4L1 copies. To our knowledge, this is the first evidence for the influence of gene copy number on the susceptibility to allograft rejection.
Results

Copy number variation in CCL4L and LT rejection
We evaluated a total of 161 LT patients and 80 healthy controls. The mean number of CCL4L copies in the control group was 1.86, a value consistent with a previously published report quantifying CCL4L in other Caucasian populations. 21 In LT patients, the mean number of CCL4L copies was 1.80. As expected, the mean and distribution of CCL4L copies in the LT patients were not statistically different to the control group (Table 1 and Supplementary Figure 1) .
For the purposes of the following analysis, LT patients were classified in several nonmutually exclusive groups: patients with AR, patients with more than one episode of AR (AR41) and patients with no acute rejection (NAR); and patients with CR and patients with no chronic rejection (NCR).
The group of NAR patients showed a statistically significantly lower mean number of CCL4L copies than AR patients (1.66 vs 1.96; P ¼ 0.014; statistical power ¼ 80.4%). Moreover, the difference in mean copy number between NAR patients and AR41 patients was even greater (1.66 vs 2.30; P ¼ 0.001; statistical power ¼ 90.3%). Moreover, no significant difference was observed between the NCR and CR patients (1.83 vs 1.77, P ¼ NS; Table 1 , Figure 1 and Supplementary Figure 1) .
After this initial analysis, we classified subjects into two groups according to the number of CCL4L copies that each individual possessed: those with 0À1 CCL4L copies, and those with X2 CCL4L copies. LT patients with X2 CCL4L copies had a significantly higher risk of AR than patients with 0-1 CCL4L copies (odds ratio, OR, 2.65; 95% confidence interval (CI), 1.33-5.28; P ¼ 0.0046; statistical power ¼ 87.9%; Table 2 ). Risk of AR in individuals with X2 CCL4L copies was even greater when we considered only the subgroup of AR41 patients (OR 8.35; 95% CI, 1.83-38.07; P ¼ 0.0007, statistical power ¼ 97.2%). Regarding CR, no significantly different risk was observed between patients possessing 0À1 copies or X2 copies of CCL4L (OR 1.06; 95% CI, 0.49-2.31; P ¼ 0.89). Thus there was evidence for association of CCL4L copy number with increased risk of AR in LT. Additionally, to assess the biological consequences of having an even higher number of CCL4L copies, we classified subjects into two groups: those with 0À2 CCL4L copies and those with X3 CCL4L copies (Supplementary Table 1 ). Interestingly, patients with X3 CCL4L copies that had already suffered one episode of AR had a significantly higher risk of suffering a second episode than patients possessing 0À2 copies of CCL4L (OR 5.25; 95% CI, 1.59-17.28; P ¼ 0.0056; statistical power ¼ 86%).
Possession of rs4796195 and rs3744595 CCL4L SNPs and rejection in LT patients
We also genotyped two functionally relevant CCL4L SNPs (rs4796195 and rs3744595) in LT patients and healthy controls, assessing the exact number of CCL4L copies belonging to each allelic variant. As expected, the allelic and genotypic frequencies between LT patients and healthy controls were similar for both SNPs (Supplementary Tables 2 and 3 ). When we performed the analysis among the different subsets of LT patients, we did not find any significant difference for the allelic and genotypic frequencies of both SNPs. Therefore, rs4796195 and rs3744595 CCL4L SNPs are not significantly associated with LT rejection.
Combined role of rs4796195 SNP and CCL4L copy number in LT rejection
In previous work, 21 we demonstrated that there is a strong correlation between CCL4L copy number and the allelic frequencies of rs4796195 CCL4L SNP (and not for the rs3744595 SNP) in the Human Genome Diversity Panel. Specifically, the frequency of rs4796195 L2 allele shows a strong positive correlation with CCL4L copy number in worldwide populations. This phenomenon also occurs in our control population and in LT patients: individuals carrying the L2 allele show a significantly higher number of CCL4L copies than those carrying only the L1 allele (Supplementary Table 4 ). Then we tested for the influence in LT rejection of CCL4L copy number of each allelic variant of rs4796195 SNP (L1 and L2). Interestingly, NAR patients had a significantly lower mean number of CCL4L1 copies than AR patients (1.49 vs 1.86; P ¼ 0.0037; statistical power ¼ 91.8%), and considerably lower number of copies than AR41 patients (1.49 vs 2.41; P ¼ 0.0005; statistical power ¼ 99.7%; Table 3 ). We found no significant differences between these groups with respect to mean number of CCL4L copies in patients carrying the L2 allele. Moreover, we did not find significant differences in copy number between chronic-rejection patients possessing either CCL4L1 or CCL4L2 copies. Thus, we conclude that there is a statistically significant association between CCL4L1 copy number and increased risk of AR in LT patients.
Discussion
Despite improvements in surgical technique, organ preservation, immunosuppression and infection management, acute organ rejection continues to present a major obstacle to successful LT. The high rates of AR in LT and the weak effect of HLA matching to predict the development of rejection after transplant suggest that genetic risks for pulmonary allograft rejection are multifactorial. 22, 23 In this study, we identified the CCL4L gene copy number as a genetic factor correlated with AR in LT. The CCL4L gene is located in a chromosome 17q12 copynumber-variable region that also includes the highly related CCL3L gene. 24 Interestingly, although there are often equivalent numbers of CCL3L and CCL4L genes, there are also haplotypes with different numbers of gene copies. This is significant because copy number of both genes can be different on a single chromosome. 14, 25 However, the number of copies of CCL3L and CCL4L is, in general, positively correlated within populations. Thus, although in this study, we focused on the therapeutic correlates of CCL4L gene copy number, CCL3L gene dosage may also contribute to the LT rejection effect.
We demonstrated that the correlation between CCL4L copy number and risk of acute LT rejection is mainly explained by the number of copies of the CCL4L1 allelic variant. This finding is consistent with the previous work showing that CCL4L1 protein is fully functional in vitro.
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In contrast, computational data suggest that the CCL4L2 protein, with a five amino-acid deletion, may show a significant loss of function. 19 Regarding the relationship between CCL4L copy number and the amount of CCL4L mRNA or protein expression, there is some, but still no conclusive, data. Although Townson et al.
14 and Gonzalez et al. 27 demonstrated that high CCL3L copy number correlates with increased functional chemokine production, the study of Townson et al. also analyzed the CCL4L gene and failed to reveal any consistent increase in CCL4L mRNA production from samples with high CCL4L copy number. However, these workers found that individuals with only one copy of CCL4L consistently had a lower expression of CCL4L than those with higher copy number. 14 We note that at the time of publication, Townson et al. were not aware of the existence of the L1 and L2 allelic variants of CCL4L, two variants that can strongly influence gene expression. 19 More recently, a study by Melzer et al. 28 reported a new cis-effect of a SNP located near the CCL4L gene (227 kb) on CCL4L protein production. They hypothesize that the effect is caused by variation in copy number of the CCL4L gene that could be in linkage disequilibrium with the analyzed SNP. Although further studies are needed to assess the effect of CCL4L copies on gene expression, we surmise that CCL4L copy number likely influences CCL4L mRNA/ protein production. Given the functional redundancy of the human CCL4 and CCL4L chemokine genes, 26 higher levels of CCL4L chemokine, related to higher CCL4L copy number, could attract more monocytes and Th1-cells, cells that are crucial to AR of LT. This concept is consistent with the role of the CCL5 chemokine in acute lung allograft rejection: in vivo neutralization of CCL5 attenuates acute lung allograft rejection and reduces allospecific responsiveness by markedly decreasing mononuclear cell recruitment. 29 In fact, CCL4L and CCL5 (together with CCL3, CCL3L and CCL4) are the main ligands of the chemokine receptor CCR5 and are predominantly expressed on T cells and monocytes or macrophages. Taken together, these data point to an important role of CCR5 ligands in acute, rather than chronic, lung allograft rejection, and suggest that perhaps mild blockage of chemotaxis with CCR5 antagonists could prevent AR in LT.
In this study, we focused on the genetic analysis of the recipients as the source of CCL4L in the rejection process was mainly their immune cells. However, we cannot completely rule out a possible contribution of donor cells on the global production of this chemokine.
In summary, our results show that CCL4L CNV and, specifically, the copy number of the CCL4L1 allelic variant is a genetic factor that may influence the risk of acute LT rejection. Further studies will be necessary to confirm these findings in independent larger series of LT patients and to assess if this effect exists in other types of transplantation. Table 5 ).
Materials and methods
The protocol of immunosuppression included high doses of steroids at the induction (first day) without any antilymphocyte antibody. This protocol was based on triple therapy with cyclosporine or tacrolimus, azathioprine or mycophenolate mofetil and low dose of steroids without discontinuing.
We diagnosed AR mainly by transbronchial biopsy findings or, in a few cases, when the patient had clinical worsening and all other conditions were ruled out. We did not perform surveillance bronchoscopies; instead, this procedure was considered only by clinical indication. We classified AR in agreement with the international consensus criteria 30 and we considered symptomatic AR to occur when the criteria level was A2 or higher. We treated AR with pulse intravenous injection of methylprednisolone at a dose of 10 mg/kg per day, over 3 days. In accord with the international consensus, we defined CR by the loss of FEV1. Information about bronchiolitis obliterans syndrome (CR) was collected at the end of the study. On the basis of immunological complications, we classified patients according to the presence or absence of acute rejection or CR. For some of the analyses, we treated the AR group according to the number of rejections that subjects demonstrated (that is, one episode of rejection vs more than one).
Estimation of CCL4L copy number
We estimated the number of CCL4L copies per study subject using methods described in detail elsewhere. 21 Briefly, the assay is based on quantification by real-time PCR in an ABI PRISM Sequence Detection System 7900 Instrument (Applied Biosystems, Foster City, CA, USA). We designed a mix of PCR primers and a TaqMan MGB to specifically amplify CCL4L. Primers and probe sequences were as follows: sense primer 5 0 -CATGGT CAGGCAGAGGAAGATG-3 0 ; antisense primer 5 0 -GCTTGCCTCTTTTGGTTTGGAAT-3 0 ; probe 5 0 -TACCA CAGGCAAGGGAT-3 0 (FAM labeled). As a control (single copy number gene), we used TaqMan RNaseP Control (Applied Biosystems) following the manufacturer's recommendations.
Genotyping of CCL4L polymorphisms
We conducted CCL4L genotyping for rs4796195 and rs3744595 SNPs as previously described. 21 This assay is performed by real-time PCR with fluorescence resonance energy transfer (FRET) probes in a LightCycler Instrument (Roche, Mannheim, Germany). For each SNP, we used a pair of specific primers for the CCL4L region where the SNP is located and a pair of FRET probes (Supplementary Table 6 ). This assay, when applied to samples in which the number of CCL4L copies is already known, allows the specific assessment of the exact number of CCL4L copies that belong to each allelic variant.
Statistical methods
We tested for association among CCL4L copy number means and type of LT rejection using the Mann-Whitney U-test. We performed analysis of association involving biallelic markers using SNPStats software. 31 ORs and 95% CIs were estimated by unconditional logistic regression analysis.
P-value lower than 0.05 indicated statistical significance. We corrected for multiple testing for the obtained P-values. A Bonferroni's correction for multiple testing (three polymorphisms tested in each group) led to a corrected threshold of about 0.017.
Power calculations were performed to give the probability of finding the differences between the CCL4L copy number means as statistically significant, given the sample size (http://www.dssresearch.com/toolkit/ spcalc/power.asp). Our study typically considered an adequate statistical power X80%.
